Vinicio de Jesus Perez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vinicio de Jesus Perez has a total of 681 co-authors. Here are the top co-authors by number of shared publications:
Ke Yuan
Division of Pulmonary Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
21 shared publicationsRoham T. Zamanian
Division of Pulmonary and Critical Care, Stanford University, Palo Alto, CA, USA
14 shared publicationsStuti Agarwal
Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA
12 shared publicationsAnanya Chakraborty
Division of Pulmonary and Critical Care, Stanford University
10 shared publications- Roham T. Zamanian
Stanford University
8 shared publications Mark E. Orcholski
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, 94305, USA
7 shared publications
Latest Publications
- 24 September 2026
- Published by Wiley in Comprehensive Physiology
- Vol. 16 (5)
Response to “From Pericytes to the Heart: A Microvascular Link in Systemic Sclerosis”
- 24 September 2026
- Published by Wiley in Comprehensive Physiology
- Vol. 16 (5)
Response to “From Pericytes to the Heart: A Microvascular Link in Systemic Sclerosis”
- Open Access
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension
Background: Sodium glucose cotransporter 2 inhibitors may improve mitochondrial biogenesis and attenuate pulmonary vascular remodeling in pulmonary arterial hypertension (PAH). We investigated the impact of empagliflozin in PAH. Methods: Microvascular endothelial cells (MVECs) were collected from the lungs of control patients and patients with PAH, and the effects of empagliflozin on MVECs were evaluated. Subsequently, treatment effects of empagliflozin (300 mg/kg chow, n=12) or placebo (n=12) were evaluated in experimental PAH rats (SU5416 injection followed by 3 weeks of hypoxia). In addition, we conducted a phase IIa proof‐of‐concept trial, EMPHOWER PoC (Feasibility Study of Empagliflozin as Treatment for Idiopathic Pulmonary Arterial Hypertension), to assess the feasibility of 12 weeks of empagliflozin treatment in patients with PAH. Results: In comparison to control MVECs, PAH MVECs showed increased protein expression of sodium glucose cotransporter 2. Empagliflozin enhanced expression of mitochondrial‐encoded genes and respiration, while attenuating oxidative stress and proliferation of PAH MVECs. In SU5416 and hypoxia rats, chronic empagliflozin treatment reduced pulmonary vascular resistance and thickening of the intima of small pulmonary arteries. Finally, 8 patients diagnosed with idiopathic and heritable PAH were enrolled in EMPHOWER PoC. No discontinuation of empagliflozin during the study period or treatment‐associated serious adverse events were observed. There were no changes in N‐terminal pro‐B‐type natriuretic peptide, World Health Organization functional class, 6‐minute walk distance, or emPHasis score; however, right ventricular ejection fraction slightly worsened (from 45%±10% to 38%±12%, P =0.031). Conclusions: Empagliflozin attenuates proliferation of PAH MVECs. Empagliflozin reduces pulmonary vascular remodeling in experimental PAH. While 12 weeks of empagliflozin treatment was feasible in patients with idiopathic or hereditary PAH, we observed signs of right ventricular deterioration. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT05493371.
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Open AccessEmpagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension
Background: Sodium glucose cotransporter 2 inhibitors may improve mitochondrial biogenesis and attenuate pulmonary vascular remodeling in pulmonary arterial hypertension (PAH). We investigated the impact of empagliflozin in PAH. Methods: Microvascular endothelial cells (MVECs) were collected from the lungs of control patients and patients with PAH, and the effects of empagliflozin on MVECs were evaluated. Subsequently, treatment effects of empagliflozin (300 mg/kg chow, n=12) or placebo (n=12) were evaluated in experimental PAH rats (SU5416 injection followed by 3 weeks of hypoxia). In addition, we conducted a phase IIa proof‐of‐concept trial, EMPHOWER PoC (Feasibility Study of Empagliflozin as Treatment for Idiopathic Pulmonary Arterial Hypertension), to assess the feasibility of 12 weeks of empagliflozin treatment in patients with PAH. Results: In comparison to control MVECs, PAH MVECs showed increased protein expression of sodium glucose cotransporter 2. Empagliflozin enhanced expression of mitochondrial‐encoded genes and respiration, while attenuating oxidative stress and proliferation of PAH MVECs. In SU5416 and hypoxia rats, chronic empagliflozin treatment reduced pulmonary vascular resistance and thickening of the intima of small pulmonary arteries. Finally, 8 patients diagnosed with idiopathic and heritable PAH were enrolled in EMPHOWER PoC. No discontinuation of empagliflozin during the study period or treatment‐associated serious adverse events were observed. There were no changes in N‐terminal pro‐B‐type natriuretic peptide, World Health Organization functional class, 6‐minute walk distance, or emPHasis score; however, right ventricular ejection fraction slightly worsened (from 45%±10% to 38%±12%, P =0.031). Conclusions: Empagliflozin attenuates proliferation of PAH MVECs. Empagliflozin reduces pulmonary vascular remodeling in experimental PAH. While 12 weeks of empagliflozin treatment was feasible in patients with idiopathic or hereditary PAH, we observed signs of right ventricular deterioration. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT05493371.
- Open Access
- 19 July 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (3) , e70373
Poverty and Social Deprivation in Patients With Pulmonary Arterial Hypertension—A PHAR Analysis
Poverty and social deprivation have been associated with impaired clinical outcomes and survival in several chronic diseases. The association between poverty and clinical outcomes in patients with pulmonary arterial hypertension (PAH) remains unclear. We aim to determine the association between federal poverty levels with healthcare use and clinical outcomes in PAH. Using the Pulmonary Hypertension Association Registry, we performed a prospective cohort analysis comparing clinical and socioeconomic characteristics in PAH patients above or below federal poverty levels. We studied the association between federal poverty levels and healthcare use patterns and transplant‐free survival using a Cox proportional hazards model. A total of 1396 participants were included, 411 (29.4%) under poverty levels. The in‐poverty group was mostly non‐White and Hispanic, had mainly public health insurance/Medicaid (37.0% vs. 5.5%; absolute standardized difference [ASD] 0.84), lower educational attainment (17.2% vs. 45.6% college graduate or higher; ASD 0.64), lower rates of employment/retirement (27.3% vs. 71.1%; ASD 0.98), higher frequency of methamphetamine exposure (31.5% vs. 9.8%; ASD 0.57), and lower frequency of idiopathic/heritable PAH (36.0% vs. 47.8%; ASD 0.65), than the not in‐poverty group. While there were no differences in severity of disease or treatment, the in‐poverty group had higher incidence rate ratios of emergency room visits and hospitalizations (IRR 2.19, 95% CI 1.99–2.40, and 1.51, 95% CI 1.36–1.68, respectively). There were no differences in transplant‐free survival ( p = 0.10). Poverty was not associated with worse survival in patients with PAH but was associated with higher rates of emergency room visits and hospitalizations, suggesting suboptimal disease control despite similar disease severity.
- 19 July 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (3) , e70373
Open AccessPoverty and Social Deprivation in Patients With Pulmonary Arterial Hypertension—A PHAR Analysis
Poverty and social deprivation have been associated with impaired clinical outcomes and survival in several chronic diseases. The association between poverty and clinical outcomes in patients with pulmonary arterial hypertension (PAH) remains unclear. We aim to determine the association between federal poverty levels with healthcare use and clinical outcomes in PAH. Using the Pulmonary Hypertension Association Registry, we performed a prospective cohort analysis comparing clinical and socioeconomic characteristics in PAH patients above or below federal poverty levels. We studied the association between federal poverty levels and healthcare use patterns and transplant‐free survival using a Cox proportional hazards model. A total of 1396 participants were included, 411 (29.4%) under poverty levels. The in‐poverty group was mostly non‐White and Hispanic, had mainly public health insurance/Medicaid (37.0% vs. 5.5%; absolute standardized difference [ASD] 0.84), lower educational attainment (17.2% vs. 45.6% college graduate or higher; ASD 0.64), lower rates of employment/retirement (27.3% vs. 71.1%; ASD 0.98), higher frequency of methamphetamine exposure (31.5% vs. 9.8%; ASD 0.57), and lower frequency of idiopathic/heritable PAH (36.0% vs. 47.8%; ASD 0.65), than the not in‐poverty group. While there were no differences in severity of disease or treatment, the in‐poverty group had higher incidence rate ratios of emergency room visits and hospitalizations (IRR 2.19, 95% CI 1.99–2.40, and 1.51, 95% CI 1.36–1.68, respectively). There were no differences in transplant‐free survival ( p = 0.10). Poverty was not associated with worse survival in patients with PAH but was associated with higher rates of emergency room visits and hospitalizations, suggesting suboptimal disease control despite similar disease severity.
- Open Access
- 30 June 2026
- Published by Wiley in Comprehensive Physiology
- Vol. 16 (4) , e70205
Lung Pericytes: Molecular Mechanisms, Signaling Pathways, and Roles in Pulmonary Diseases
Pericytes are specialized mural cells that ensheathe microvessels and play critical roles in maintaining vascular homeostasis, regulating angiogenesis, and coordinating tissue repair. Studies in the systemic circulation have established that pericytes contribute to the pathogenesis of major vascular diseases, including stroke, myocardial infarction, and retinopathy, increasing interest in understanding their roles in both health and disease. In contrast, our understanding of pericyte biology in the lung remains relatively limited. Over the past 15 years, a growing body of evidence emphasizes that lung pericytes actively participate in vascular remodeling and inflammatory responses, pointing to an important role for these cells in the pathogenesis of multiple pulmonary diseases. This comprehensive review synthesizes current knowledge on the molecular mechanisms governing lung pericyte function, with particular emphasis on key signaling pathways including PDGF‐BB/PDGFRβ, TGFβ/ALK1/ALK5, VEGF/VEGFR, Angiopoietin/Tie2, Notch, Wnt, and sphingosine‐1‐phosphate (S1P). We examine how these pathways orchestrate pericyte recruitment, proliferation, differentiation, and phenotypic transitions through complex downstream signaling cascades involving kinases, transcription factors, and mechanotransduction mechanisms. The review further explores the multifaceted roles of pericytes in major pulmonary diseases, including acute lung injury and acute respiratory distress syndrome (ALI/ARDS), pulmonary fibrosis, pulmonary arterial hypertension (PAH), lung cancer, and lung infections.
- 30 June 2026
- Published by Wiley in Comprehensive Physiology
- Vol. 16 (4) , e70205
Open AccessLung Pericytes: Molecular Mechanisms, Signaling Pathways, and Roles in Pulmonary Diseases
Pericytes are specialized mural cells that ensheathe microvessels and play critical roles in maintaining vascular homeostasis, regulating angiogenesis, and coordinating tissue repair. Studies in the systemic circulation have established that pericytes contribute to the pathogenesis of major vascular diseases, including stroke, myocardial infarction, and retinopathy, increasing interest in understanding their roles in both health and disease. In contrast, our understanding of pericyte biology in the lung remains relatively limited. Over the past 15 years, a growing body of evidence emphasizes that lung pericytes actively participate in vascular remodeling and inflammatory responses, pointing to an important role for these cells in the pathogenesis of multiple pulmonary diseases. This comprehensive review synthesizes current knowledge on the molecular mechanisms governing lung pericyte function, with particular emphasis on key signaling pathways including PDGF‐BB/PDGFRβ, TGFβ/ALK1/ALK5, VEGF/VEGFR, Angiopoietin/Tie2, Notch, Wnt, and sphingosine‐1‐phosphate (S1P). We examine how these pathways orchestrate pericyte recruitment, proliferation, differentiation, and phenotypic transitions through complex downstream signaling cascades involving kinases, transcription factors, and mechanotransduction mechanisms. The review further explores the multifaceted roles of pericytes in major pulmonary diseases, including acute lung injury and acute respiratory distress syndrome (ALI/ARDS), pulmonary fibrosis, pulmonary arterial hypertension (PAH), lung cancer, and lung infections.
- Open Access
- 11 June 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (9) , 2199-2210
Identification of Pulmonary Arterial Hypertension Patients with Venous or Capillary Involvement
Rationale: While therapeutic advances have improved survival in Group 1 Pulmonary Arterial Hypertension (PAH), patients with Group 1.5 “PAH with features of venous/capillary involvement” (formerly Pulmonary Veno-Occlusive Disease or Pulmonary Capillary Hemangiomatosis, now collectively termed PVOD/PCH) remain underrecognized, develop serious complications from usual PAH therapy titrations, and suffer high mortality awaiting necessary lung transplant. Identifying PVOD/PCH early before therapy initiation could aid management and expedite transplant referral. Objective: We aimed to develop a likelihood score distinguishing PVOD/PCH from other forms of PAH using clinical variables. Methods: Due to low PVOD/PCH prevalence and no dedicated registries, we leveraged published case control/series studies to assess the ability of several clinical variables to discriminate PVOD/PCH from PAH. From pooled literature-derived data, we performed Sensitivity/Specificity and simulation-based Receiver Operator Characteristic (ROC) analyses to estimate variable performance. Top-performing variables formed a PVOD/PCH Likelihood score, which had its accuracy tested for distinguishing histopathology-confirmed PVOD/PCH cases (n = 37) from PAH controls (n = 60) in three cohorts of transplant-eligible patients from the United States, Spain, and the Netherlands. Measurements and Main Results: DLCO, six-minute walk desaturation, PaO2, sex, smoking history, CT septal line thickening, and CT lymphadenopathy had the highest sensitivity and specificity performance and were incorporated into the PVOD score. Across test cohorts, the score achieved a ROC area under the curve of 0.97 (95% CI 0.93-1.00) for discriminating PVOD/PCH and it retained accuracy when data were missing. Conclusions: This score could facilitate early PVOD/PCH identification in incident PAH, potentially helping expedite transplant referral and informing therapy initiation/titration decisions.
- 11 June 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (9) , 2199-2210
Open AccessIdentification of Pulmonary Arterial Hypertension Patients with Venous or Capillary Involvement
Rationale: While therapeutic advances have improved survival in Group 1 Pulmonary Arterial Hypertension (PAH), patients with Group 1.5 “PAH with features of venous/capillary involvement” (formerly Pulmonary Veno-Occlusive Disease or Pulmonary Capillary Hemangiomatosis, now collectively termed PVOD/PCH) remain underrecognized, develop serious complications from usual PAH therapy titrations, and suffer high mortality awaiting necessary lung transplant. Identifying PVOD/PCH early before therapy initiation could aid management and expedite transplant referral. Objective: We aimed to develop a likelihood score distinguishing PVOD/PCH from other forms of PAH using clinical variables. Methods: Due to low PVOD/PCH prevalence and no dedicated registries, we leveraged published case control/series studies to assess the ability of several clinical variables to discriminate PVOD/PCH from PAH. From pooled literature-derived data, we performed Sensitivity/Specificity and simulation-based Receiver Operator Characteristic (ROC) analyses to estimate variable performance. Top-performing variables formed a PVOD/PCH Likelihood score, which had its accuracy tested for distinguishing histopathology-confirmed PVOD/PCH cases (n = 37) from PAH controls (n = 60) in three cohorts of transplant-eligible patients from the United States, Spain, and the Netherlands. Measurements and Main Results: DLCO, six-minute walk desaturation, PaO2, sex, smoking history, CT septal line thickening, and CT lymphadenopathy had the highest sensitivity and specificity performance and were incorporated into the PVOD score. Across test cohorts, the score achieved a ROC area under the curve of 0.97 (95% CI 0.93-1.00) for discriminating PVOD/PCH and it retained accuracy when data were missing. Conclusions: This score could facilitate early PVOD/PCH identification in incident PAH, potentially helping expedite transplant referral and informing therapy initiation/titration decisions.
- Open Access
A Perturb-seq screen guided by species divergence uncovers pathways for collateral artery formation
Collateral arteries are natural bypasses that can reroute blood flow around arterial blockages, limiting tissue injury during stroke and coronary artery disease. Despite their clinical effectiveness, therapeutic strategies to stimulate collateral artery growth remain unavailable due to our limited understanding of their developmental mechanisms. Remarkably, guinea pigs display exceptionally dense collateral artery networks across various organs, resulting in complete resistance to ischemic damage in the brain and heart. In this study, we compared single-cell RNA sequencing (scRNA-seq) from guinea pig and mouse tissues to identify endothelial cell (EC) gene expression patterns associated with extensive collateral artery development. We then developed an in vivo Perturb-seq platform in mice to test whether genes differentially expressed in guinea pigs influence artery EC specification. This pipeline identified artery repressors that were downregulated in guinea pigs and increased pial collateral abundance when inhibited in mice. Downstream analysis suggests that artery repressors, including WNT and hypoxia response genes, function in two capillary EC subsets— Esm1+ pre-artery and Apln+ angiogenic tip cells. Reduced activity of these repressors allows more ECs to acquire arterial identity, potentiating collateral artery formation. Collectively, our study establishes a strategy for discovering the genes underlying species-specific traits, suggests that guinea pigs have collaterals due to decreased activity of artery inhibitor pathways and hypoxia responses, and identifies novel targets for stimulating collateral artery formation ( Graphical abstract ). Abstract Figure:
Open AccessA Perturb-seq screen guided by species divergence uncovers pathways for collateral artery formation
Collateral arteries are natural bypasses that can reroute blood flow around arterial blockages, limiting tissue injury during stroke and coronary artery disease. Despite their clinical effectiveness, therapeutic strategies to stimulate collateral artery growth remain unavailable due to our limited understanding of their developmental mechanisms. Remarkably, guinea pigs display exceptionally dense collateral artery networks across various organs, resulting in complete resistance to ischemic damage in the brain and heart. In this study, we compared single-cell RNA sequencing (scRNA-seq) from guinea pig and mouse tissues to identify endothelial cell (EC) gene expression patterns associated with extensive collateral artery development. We then developed an in vivo Perturb-seq platform in mice to test whether genes differentially expressed in guinea pigs influence artery EC specification. This pipeline identified artery repressors that were downregulated in guinea pigs and increased pial collateral abundance when inhibited in mice. Downstream analysis suggests that artery repressors, including WNT and hypoxia response genes, function in two capillary EC subsets— Esm1+ pre-artery and Apln+ angiogenic tip cells. Reduced activity of these repressors allows more ECs to acquire arterial identity, potentiating collateral artery formation. Collectively, our study establishes a strategy for discovering the genes underlying species-specific traits, suggests that guinea pigs have collaterals due to decreased activity of artery inhibitor pathways and hypoxia responses, and identifies novel targets for stimulating collateral artery formation ( Graphical abstract ). Abstract Figure:
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4) , e25881
Loss of ROR2 Tyrosine Kinase Receptor Is Associated With Endothelial Dysfunction in PAH via Inappropriate Integrin β1 Activation
BACKGROUND: Endothelial dysfunction is a key feature of pulmonary arterial hypertension (PAH). Previously, we demonstrated decreased Wnt7a transcript levels, causing reduced angiogenesis in PAH. Wnt7a expression correlates with tip formation via ROR2 (receptor tyrosine kinase-like orphan receptor 2), a tyrosine kinase receptor. We hypothesized that ROR2 activation in pulmonary microvascular endothelial cells (PMVECs) promotes angiogenesis, particularly endothelial barrier establishment, and its loss causes PAH. METHODS: Endothelial-specific ROR2 knockout (ROR2 ECKO) and wild-type mice were studied under normoxia and chronic hypoxia using echocardiography, hemodynamics, and lung morphometry. PMVECs from healthy and PAH lungs were transfected with ROR2 siRNA/constructs for functional and molecular studies. Focal adhesion activation and force generation were assessed via Förster resonance energy transfer-based methods. Bulk and single-cell transcriptomic analyses were performed on siROR2 (ROR2 siRNA) PMVECs and ROR2 ECKO lungs. RESULTS: ROR2 ECKO mice exacerbated pulmonary hypertension and vascular remodeling in hypoxia. Single-cell RNA-sequencing of lung endothelial cells revealed dysregulated barrier formation and angiogenesis. Evans blue dye extravasation confirmed reduced endothelial barrier integrity in ROR2 ECKO mice. ROR2-deficient PAH PMVECs displayed increased adhesion, permeability, and focal adhesion numbers, with reduced VE-cadherin at cell junctions. Confocal imaging and foster resonance energy transfer revealed ROR2 localization in focal adhesions, interacting with ITGB1 (integrin β1) which remained in an active, adhesion-promoting state in ROR2-deficient cells. Restoring ROR2 in PAH PMVECs normalized adhesion, barrier function, and focal adhesion abundance. Transcriptomic analysis revealed Rab12 mediated ROR2-ITGB1 crosstalk, whose knockdown mimicked ROR2 deficiency in PMVECs. CONCLUSIONS: ROR2 regulates pulmonary angiogenesis by maintaining endothelial barrier integrity and facilitating integrin recycling. ROR2 restoration could be a potential therapeutic approach for PAH.
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4) , e25881
Loss of ROR2 Tyrosine Kinase Receptor Is Associated With Endothelial Dysfunction in PAH via Inappropriate Integrin β1 Activation
BACKGROUND: Endothelial dysfunction is a key feature of pulmonary arterial hypertension (PAH). Previously, we demonstrated decreased Wnt7a transcript levels, causing reduced angiogenesis in PAH. Wnt7a expression correlates with tip formation via ROR2 (receptor tyrosine kinase-like orphan receptor 2), a tyrosine kinase receptor. We hypothesized that ROR2 activation in pulmonary microvascular endothelial cells (PMVECs) promotes angiogenesis, particularly endothelial barrier establishment, and its loss causes PAH. METHODS: Endothelial-specific ROR2 knockout (ROR2 ECKO) and wild-type mice were studied under normoxia and chronic hypoxia using echocardiography, hemodynamics, and lung morphometry. PMVECs from healthy and PAH lungs were transfected with ROR2 siRNA/constructs for functional and molecular studies. Focal adhesion activation and force generation were assessed via Förster resonance energy transfer-based methods. Bulk and single-cell transcriptomic analyses were performed on siROR2 (ROR2 siRNA) PMVECs and ROR2 ECKO lungs. RESULTS: ROR2 ECKO mice exacerbated pulmonary hypertension and vascular remodeling in hypoxia. Single-cell RNA-sequencing of lung endothelial cells revealed dysregulated barrier formation and angiogenesis. Evans blue dye extravasation confirmed reduced endothelial barrier integrity in ROR2 ECKO mice. ROR2-deficient PAH PMVECs displayed increased adhesion, permeability, and focal adhesion numbers, with reduced VE-cadherin at cell junctions. Confocal imaging and foster resonance energy transfer revealed ROR2 localization in focal adhesions, interacting with ITGB1 (integrin β1) which remained in an active, adhesion-promoting state in ROR2-deficient cells. Restoring ROR2 in PAH PMVECs normalized adhesion, barrier function, and focal adhesion abundance. Transcriptomic analysis revealed Rab12 mediated ROR2-ITGB1 crosstalk, whose knockdown mimicked ROR2 deficiency in PMVECs. CONCLUSIONS: ROR2 regulates pulmonary angiogenesis by maintaining endothelial barrier integrity and facilitating integrin recycling. ROR2 restoration could be a potential therapeutic approach for PAH.
- 25 March 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (6) , 831-839
Expanding the genetic burden of low-evidence genes in pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a severe disease characterized by elevated pulmonary artery pressure, leading to heart failure and premature death if untreated. Genetic factors significantly contribute to PAH, and several genes have been linked to its development. According to the ClinGen PH-GCEP group, 12 genes have definitive evidence of association with PAH, three have moderate evidence, six have limited evidence, and five remain disputed due to insufficient genetic data. The aim of this study was to analyze variants in genes without definitive evidence in a cohort of 1480 individuals (954 PAH patients and 526 relatives) by next-generation sequencing (NGS). Variants were prioritized through a custom pipeline developed in-house and classification was performed according to ACMG guidelines. A total of 32 different variants were identified in 42 individuals (32 patients and 10 relatives, five of whom developed the disease): Two pathogenic or likely pathogenic variants in ABCC8 and 30 variants of unknown significance (VUS) in 10 genes (ABCC8, AQP1, BMPR1A, BMPR1B, BMP10, FBLN2, NOTCH3, SMAD1, SMAD4 and TET2). On the opposite, no candidate variants were detected in GGCX, KLF2, KLK1 or PDGFD genes. These findings provide further genetic evidence supporting the association of ABCC8 and related genes with PAH, while no candidate variants were detected in GGCX, KLF2, KLK1, or PDGFD. Further research is needed to confirm the functional impact of these variants.
- 25 March 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (6) , 831-839
Expanding the genetic burden of low-evidence genes in pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a severe disease characterized by elevated pulmonary artery pressure, leading to heart failure and premature death if untreated. Genetic factors significantly contribute to PAH, and several genes have been linked to its development. According to the ClinGen PH-GCEP group, 12 genes have definitive evidence of association with PAH, three have moderate evidence, six have limited evidence, and five remain disputed due to insufficient genetic data. The aim of this study was to analyze variants in genes without definitive evidence in a cohort of 1480 individuals (954 PAH patients and 526 relatives) by next-generation sequencing (NGS). Variants were prioritized through a custom pipeline developed in-house and classification was performed according to ACMG guidelines. A total of 32 different variants were identified in 42 individuals (32 patients and 10 relatives, five of whom developed the disease): Two pathogenic or likely pathogenic variants in ABCC8 and 30 variants of unknown significance (VUS) in 10 genes (ABCC8, AQP1, BMPR1A, BMPR1B, BMP10, FBLN2, NOTCH3, SMAD1, SMAD4 and TET2). On the opposite, no candidate variants were detected in GGCX, KLF2, KLK1 or PDGFD genes. These findings provide further genetic evidence supporting the association of ABCC8 and related genes with PAH, while no candidate variants were detected in GGCX, KLF2, KLK1, or PDGFD. Further research is needed to confirm the functional impact of these variants.
- Open Access
- 10 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 11026
Patient-derived colon epithelial organoids reveal lipid-related metabolic dysfunction in pediatric ulcerative colitis
Ulcerative colitis (UC) is associated with epithelial metabolic derangements which exacerbate gut inflammation. Here, we develop colon organoid (colonoid) lines from pediatric patients with endoscopically active UC, inactive UC, and those without intestinal inflammation to interrogate functional metabolic differences in the colon epithelia. We demonstrate that active UC colonoids exhibit hypermetabolic features and cellular stress, specifically during differentiation. Hypermetabolism in active UC colonoids is driven, in part, by increased proton leak, and excess lipid accumulation. Active UC colonoids exhibit heightened activation of the master lipid regulator PPAR-α and its transcriptional pathways. Pharmacological PPAR-α inhibition limits lipid accumulation, induces a metabolic shift towards glucose utilization, suppresses hypermetabolism, and reduces chemokine secretion and cellular stress markers. Collectively, our findings identify lipid-related metabolic dysfunction as a key pathologic feature of the pediatric UC epithelium and highlight the potential of patient-derived colonoids as a preclinical model for evaluating epithelial-targeted therapies addressing this dysfunction.
- 10 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 11026
Open AccessPatient-derived colon epithelial organoids reveal lipid-related metabolic dysfunction in pediatric ulcerative colitis
Ulcerative colitis (UC) is associated with epithelial metabolic derangements which exacerbate gut inflammation. Here, we develop colon organoid (colonoid) lines from pediatric patients with endoscopically active UC, inactive UC, and those without intestinal inflammation to interrogate functional metabolic differences in the colon epithelia. We demonstrate that active UC colonoids exhibit hypermetabolic features and cellular stress, specifically during differentiation. Hypermetabolism in active UC colonoids is driven, in part, by increased proton leak, and excess lipid accumulation. Active UC colonoids exhibit heightened activation of the master lipid regulator PPAR-α and its transcriptional pathways. Pharmacological PPAR-α inhibition limits lipid accumulation, induces a metabolic shift towards glucose utilization, suppresses hypermetabolism, and reduces chemokine secretion and cellular stress markers. Collectively, our findings identify lipid-related metabolic dysfunction as a key pathologic feature of the pediatric UC epithelium and highlight the potential of patient-derived colonoids as a preclinical model for evaluating epithelial-targeted therapies addressing this dysfunction.
- 10 October 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (13) , 1981-1982
The devil is in the details: addressing lung cell heterogeneity in sugen-hypoxia rats and its relevance to pulmonary arterial hypertension
- 10 October 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (13) , 1981-1982
The devil is in the details: addressing lung cell heterogeneity in sugen-hypoxia rats and its relevance to pulmonary arterial hypertension